Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.4K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.4K
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

396
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
396
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.3K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.1K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.1K
Drug Nomenclature01:17

Drug Nomenclature

2.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
2.7K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency-Domain Transformation of cfDNA End-Motif Profiles Enhances Robust Cancer Detection.

Genes·2026
Same author

Multi-to-uni modal knowledge transfer pre-training for molecular representation learning.

Nature communications·2026
Same author

Early cancer detection via multi-omics cfDNA fragmentation using early-late fusion neural network with sample-modality evaluation.

Briefings in bioinformatics·2025
Same author

cfMethDB: A Comprehensive cfDNA Methylation Data Resource for Cancer Biomarkers.

Genomics, proteomics & bioinformatics·2025
Same author

IPFMC: an iterative pathway fusion approach for enhanced multi-omics clustering in cancer research.

Briefings in bioinformatics·2024
Same author

Machine Learning-Based Detection of Bladder Cancer by Urine cfDNA Fragmentation Hotspots that Capture Cancer-Associated Molecular Features.

Clinical chemistry·2024
Same journal

Tissue MicroRNAs in Arrhythmogenic Cardiomyopathy: A Systematic Review of Studies in Human Myocardium and Animal Models with Implications for Post-Mortem Molecular Diagnostics.

Genes·2026
Same journal

Genetic Variants and Dental Caries Susceptibility: An Umbrella Review and Multilevel Meta-Analysis.

Genes·2026
Same journal

Generative AI and Language Models in Human Genetics and Health: From Variant Interpretation to Clinical Decision Support.

Genes·2026
Same journal

Familial White-Sutton Syndrome Caused by a Pathogenic POGZ p.Arg508* Variant: Intrafamilial Variability from Childhood to Adulthood.

Genes·2026
Same journal

Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia.

Genes·2026
Same journal

THBS1 as a Key Regulator of Myoblasts: Validation of Its Inhibitory Roles in Skeletal Muscle Development.

Genes·2026
See all related articles

Related Experiment Video

Updated: Nov 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K

MNBDR: A Module Network Based Method for Drug Repositioning.

He-Gang Chen1, Xiong-Hui Zhou1

  • 1Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, China.

Genes
|December 30, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces Module Network Based Drug Repositioning (MNBDR), a novel method for drug repurposing. MNBDR effectively identifies potential drug candidates by analyzing gene modules and their interactions, outperforming existing approaches.

Keywords:
drug repositioningmodule networkrandom walk algorithmsystems biology

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

3.6K

Related Experiment Videos

Last Updated: Nov 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

3.6K

Area of Science:

  • Computational Biology
  • Pharmacology
  • Bioinformatics

Background:

  • Drug repurposing accelerates development by finding new uses for existing drugs.
  • Current methods often overlook gene module interactions crucial for drug response.
  • Integrating gene expression and protein-protein interaction data is vital for accurate drug repositioning.

Purpose of the Study:

  • To develop a novel drug repurposing method, Module Network Based Drug Repositioning (MNBDR).
  • To leverage gene module cross-talks for improved prediction of drug-disease associations.
  • To identify reliable drug candidates for diseases by considering pathway interactions.

Main Methods:

  • Constructed a module network from protein-protein interaction (PPI) data to represent cross-talks among gene modules.
  • Integrated human gene expression profiles of drug-stimulated and disease samples.
  • Applied random walk algorithms and a novel indicator to screen potential drugs based on essential disease modules.

Main Results:

  • MNBDR demonstrated superior performance compared to existing popular drug repurposing methods.
  • The method successfully identified potential drug candidates for various diseases.
  • Functional analysis revealed that MNBDR uncovers key biological mechanisms underlying drug response.

Conclusions:

  • MNBDR offers a more effective approach to drug repurposing by incorporating module network information.
  • The method enhances the prediction of drug-disease associations by considering pathway cross-talks.
  • MNBDR provides insights into the biological mechanisms of drug action, aiding in drug development.